Osteopontin is associated with decreased apoptosis and αv integrin expression in lung adenocarcinoma

Acta Histochemica

Volumn 116, Issue 1, 2014, Pages 222-229

  Štemberger, Christophe ^a   Matušan Ilijaš, Koviljka ^b   Avirović, Manuela ^b   Bulat Kardum, Ljiljana ^a   Ivančić, Aldo ^a   Jonjić, Nives ^b   Lučin, Ksenija ^b  

^a KBC RIJEKA   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

v Integrin; Apoptosis; Immunohistochemistry; Lung carcinoma; Osteopontin; Tissue array analysis

Indexed keywords

CD51 ANTIGEN; OSTEOPONTIN;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; FEMALE; HUMAN; LUNG; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; FEMALE; HUMANS; INTEGRIN ALPHAV; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; OSTEOPONTIN;

EID: 84894900867     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2013.07.009     Document Type: Article

References (35)

1. Bellahcène A., Castronovo V., Ogbureke K.U., Fisher L.W., Fedarko N.S. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 2008, 8:212-226.
2. Blasberg J.D., Goparaju C.M., Pass H.I., Donington S. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thor Cardiovasc Surg 2010, 139:1587-1593.
3. Boldrini L., Donati V., Dell'Omodarme M., Prati M.C., Faviana P., Camacci T., et al. Prognostic significance of osteopontin expression in early stage non-small cell lung cancer. Br J Cancer 2005, 93:453-457.
4. Courter D., Cao H., Kwok S., Kong C., Banh A., Kuo P., et al. The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS ONE 2010, 5(3):e9633.
5. Cox D., Brennan M., Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010, 9:804-820.
6. Cui R., Takahashi F., Ohashi R., Gu T., Yoshioka M., Nishio K., et al. Abrogation of the interaction between osteopontin and αvβ3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 2007, 57:302-310.
7. Cui R., Takahashi F., Ohashi R., Yoshioka M., Gu T., Tajima K., et al. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer 2009, 63:368-374.
8. Donati V., Boldrini L., Dell Omodarme M., Prati M.C., Faviana P., Cammaci T., et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 2005, 11:6459-6465.
9. Fong Y.C., Liu S.C., Huang C.Y., Li T.M., Hsu S.F., Kao S.T., et al. Osteopontin increases lung cancer cell migration via activation of the αvβ3 integrin/FAK/Akt and NF-kB-dependent pathway. Lung Cancer 2009, 263-270.
10. Frey A.B., Wali A., Pass H., Lonardo F. Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. Histopathology 2007, 50:720-726.
11. Geissinger E., Weisser C., Fischer P., Schartl M., Wellbrock C. Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. Cancer Res 2002, 62:4820-4828.
12. Giancotti F.G., Ruoslahti E. Integrin signalling. Science 1999, 285(5430):1028-1032.
13. Hu Z., Lin D., Yuan J., Xiao T., Zhang H., Sun W., et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005, 11:4646-4652.
14. Jin Y., Tong D., Chen J., Feng Z., Yang J., Shao C., et al. Overexpression of osteopontin, αvβ3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer. PLoS ONE 2012, 7(10):e48575.
15. Lin Y.H., Yang-Yen H.F. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 2001, 276:46024-46030.
16. Mack P., Redman M.W., Chansky K., Williamson S.K., Farneth N.C., Lara P.N., et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy: SWOG study S0003. J Clin Oncol 2008, 26:4766-4771.
17. Matušan-Ilijaš K., Damante G., Fabbro D., Dordević G., Hadžisejdić I., Grahovac M., et al. Osteopontin expression correlates with nuclear factor-κB activation and apoptosis downregulation in clear cell renal cell carcinoma. Pathol Res Pract 2011, 207:104-110. 15.
18. Ni Q., Ji H., Zhao Z., Fan X., Endostar Xu C. a modified endostatin inhibits non small cell lung cancer in vitro invasion through osteopontin-related mechanism. Mol Cell Pharm 2009, 614:1-6.
19. Pang H., Cai L., Yang Y., Chen X., Sui G., Zhao C. Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. Cancer Biother Radiopharm 2011, 26:165-173.
20. Polat B., Wohlleben G., Katzer A., Djuzenova C.S., Technau A., Flentje M. Influence of osteopontin silencing on survival and migration of lung cancer cells. Strahlenther Onkol 2013, 189:62-67.
21. Rud A.K., Lund-Iversen M., Berge G., Brustugun O.T., Solberg S.K., Mælandsmo G., et al. Expression of S100A4, ephrin-A1 and osteopontin in non-small lung cancer. BMC Cancer 2012, 12:333-342.
22. Scatena M., Almeida M., Chaisson M.L., Fausto N., Nicosia R.F., Giachelli C.M. NF-kappa mediates αvβ3 integrin-induced endothelial cell survival. J Cell Biol 1998, 141:1083-1093.
23. Schneider S., Yochim J.M., Brabender J., Uchida K., Danenberg K.D., Metzger R., et al. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 2004, 10:1588-1596.
24. Shevde L.A., Das S., Clark D.W., Samant R.S. Osteopontin: an effector and an effect of tumor metastasis. Curr Molecular Med 2010, 10:71-81.
25. Shijubo N., Kojima H., Nagata M., Ohchi T., Suzuki A., Abe S., et al. Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech 2003, 60:186-198.
26. Song G., Ming Y., Mao Y., Bao S., Ouyang G. Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via αvβ3 integrins in human gastric cancer cells. Exp Biol Med 2008, 233:1537-1545.
27. Stendal T., Borset M., Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 2004, 26:179-184.
28. Stewart D.J. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010, 75:173-234.
29. Townson J.L., Naumov G.N., Chambers A.F. The role of apoptosis in tumor progression and metastasis. Curr Mol Med 2003, 3:631-642.
30. Wai P.Y., Kuo P.C. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008, 10:3-18.
31. Wang X.M., Li J., Yan M.X., Liu L., Jia D.S., Geng Q., et al. Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer. PLoS ONE 2012, 8(2):e5571.
32. Weber G.F., Lett G.S., Haubein N.C. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010, 103:861-869.
33. Zhang J., Takahashi K., Takahashi F., Shimizu K., Ohsita F., Kameda Y., et al. Differential osteopontin expression in lung cancer. Cancer Lett 2001, 171:215-222.
34. Zhao J., Dong L., Wu G., Xu D., Chen J., Li K., et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008, 135:956-968.
35. Zohar R., Zhu B., Liu Sodek J., McCulloch C.A. Increased cell death in osteopontin-deficient cardiac fibroblasts occurs by a caspase-3-independent pathway. Am J Physiol Heart Circ Physiol 2004, 287:1730-1739.